Colon AdenocarcinomaPhase 2NCT02368886
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
A Phase 2 study testing Clobetasol Propionate, Pharmacological Study and Quality-of-Life Assessment in people with Colon Adenocarcinoma and Rectal Adenocarcinoma, run by Academic and Community Cancer Research United at 22 sites in United States.
Trial summary
This randomized phase II trial studies how well lower-dose compared to standard dose regorafenib works in treating patients with colorectal cancer that has spread from the primary site (place where it started) to other places in the body and does not respond to treatment. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Colon Adenocarcinoma, Rectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v7
- What is being tested?
- Clobetasol Propionate, Pharmacological Study and Quality-of-Life Assessment
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 123 participants
- Where
- 22 sitesUnited States
- Study dates
- 27 Mar 2015to 2 Mar 2023
- Phase
- Phase 2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Histological or cytological documentation of adenocarcinoma of the colon or rectum
- Advanced or metastatic colorectal cancer with no curative options available and progression on previous standard therapy, including an EGFR inhibitor if KRAS wild-type
- Measurable or non-measurable disease
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
- Life expectancy of >= 3 months
- Absolute neutrophil count (ANC) > 1500/mm^3 (obtained =< 7 days prior to randomization)
Show all 19Show fewer
- Platelet count > 100,000/mm^3 (obtained =< 7 days prior to randomization)
- Hemoglobin > 9.0 g/dL (obtained =< 7 days prior to randomization)
- Total bilirubin =< 1.5 x upper limit of normal (ULN) (obtained =< 7 days prior to randomization)
- Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer) (obtained =< 7 days prior to randomization)
- Serum creatinine =< 1.5 x ULN (obtained =< 7 days prior to randomization)
- International normalized ratio (INR)/partial thromboplastin time (PTT) =< 1.5 x ULN (obtained =< 7 days prior to randomization)
- NOTE: patients who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists; close monitoring of at least weekly evaluations will be performed until INR/PTT is stable based on a measurement that is pre-dose as defined by the local standard of care
- Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for patients with liver involvement of their cancer) (obtained =< 7 days prior to randomization)
- Negative serum pregnancy test done =< 7 days prior to randomization, for women of childbearing potential only; note: post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test; the definition of adequate contraception will be based on the judgment of the investigator
- Ability to complete questionnaire(s) by themselves or with assistance
- Provide informed written consent
- Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
- Willing to provide blood samples for correlative research and banking purposes
Who cannot join
- Prior treatment with regorafenib
- Major surgical procedure, open biopsy, or significant traumatic injury =< 28 days prior to randomization
- Congestive heart failure > New York Heart Association (NYHA) class 2
- Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months) or myocardial infarction less than 6 months prior to randomization
- Cardiac arrhythmias requiring anti-arrhythmic therapy; Note: pace makers, beta blockers, or digoxin are permitted
- Uncontrolled hypertension; (systolic blood pressure > 140 mmHg or diastolic pressure > 90 mmHg despite optimal medical management)
Show all 40Show fewer
- History of or current pheochromocytoma
- Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism =< 6 months prior to randomization
- Ongoing infection > grade 2 National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
- Known history of chronic hepatitis B or C
- Patients with seizure disorder requiring medication
- Symptomatic metastatic brain or meningeal tumors unless the patient is > 6 months from definitive therapy, has a negative imaging study within 4 weeks of randomization and is clinically stable with respect to the tumor at the time of randomization; note: patient must not be undergoing acute steroid therapy or taper (chronic steroid therapy is acceptable provided that the dose is stable for one month prior to and following screening radiographic studies)
- History of organ allograft (including corneal transplant)
- Evidence or history of bleeding diathesis or any hemorrhage or bleeding event > CTCAE grade 3 =< 4 weeks prior to randomization
- Non-healing wound, ulcer, or bone fracture
- Renal failure requiring hematological (hemo-) or peritoneal dialysis
- Dehydration CTCAE (version 4.0) grade >= 1
- Substance abuse, medical, psychological or social conditions that may interfere with the patient?s participation in the study or evaluation of the study results
- Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation
- Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
- Persistent proteinuria of Common Toxicity Criteria (CTC) grade 3 or higher (>= 3.5 g/24 hours [hrs])
- Patients unable to swallow oral medications
- Any malabsorption condition
- Unresolved toxicity greater than CTCAE (version 4.0) grade 1 attributed to any prior therapy/procedure excluding alopecia and oxaliplatin induced neurotoxicity =< grade 2
- Albumin levels < 2.5 g/dl
- Any of the following:
- Pregnant women
- Nursing women
- Men or women of childbearing potential who are unwilling to employ adequate contraception
- NOTE: men and women of childbearing potential must agree to use adequate contraception beginning at the signing of the informed consent form (ICF) until at least 3 months after the last dose of study drug; the definition of adequate contraception will be based on the judgment of the principal investigator or a designated associate
- Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
- Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; NOTE: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
- Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
- Previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer within 3 years prior to randomization EXCEPT for curatively treated cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors (Ta [non-invasive tumor], Tis [carcinoma in situ] and T1 [tumor invades lamina propria]); note: all cancer treatments for cancers that were distinct in a primary site other than colorectal must be completed at least 3 years prior to randomization (i.e., signature date of the informed consent form)
- Pleural effusion or ascites that causes respiratory compromise (>= CTCAE version 4.0 grade 2 dyspnea)
- Concurrent anti-cancer therapy =< 4 weeks from registration (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization)
- Current use of clobetasol propionate
- Use of any herbal remedy (e.g. St. John?s wort [Hypericum perforatum])
- Patients unable to ambulate or who have amputations or paralysis of any extremity
- History of contact dermatitis to clobetasol propionate or similarly fluorinated steroids or other steroids with the propionate ester
Trial locations and contacts
22 sites in 1 country.
22 sites in 1 country
United States22 sites
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215
Roswell Park Cancer Institute
Buffalo, New York, 14263
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210
Geisinger Medical Center
Danville, Pennsylvania, 17822
Hematology Oncology Associates of Central New York-East Syracuse
East Syracuse, New York, 13057
Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin, 54301
Wellmont Medical Associates Oncology and Hematology-Kingsport
Kingsport, Tennessee, 37660
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033
Marshfield Clinic
Marshfield, Wisconsin, 54449
Missouri Valley Cancer Consortium
Omaha, Nebraska, 68106
University of Nebraska Medical Center
Omaha, Nebraska, 68198
Illinois CancerCare-Peoria
Peoria, Illinois, 61615
Mayo Clinic Hospital
Phoenix, Arizona, 85054
Mayo Clinic
Rochester, Minnesota, 55905
Metro Minnesota Community Oncology Research Consortium
Saint Louis Park, Minnesota, 55416
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259
University of Washington Medical Center
Seattle, Washington, 98195
Siouxland Regional Cancer Center
Sioux City, Iowa, 51101
Northern Indiana Cancer Research Consortium
South Bend, Indiana, 46628
Washington University School of Medicine
St Louis, Missouri, 63110
Toledo Clinic Cancer Centers-Toledo
Toledo, Ohio, 43623
Wake Forest University Health Sciences
Winston-Salem, North Carolina, 27157
About this study
Official title: Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)
This randomized phase II trial studies how well lower-dose compared to standard dose regorafenib works in treating patients with colorectal cancer that has spread from the primary site (place where it started) to other places in the body and does not respond to treatment. Regorafenib may stop the growth of colorectal cancer by blocking the growth of new blood vessels necessary for tumor growth and by blocking some of the enzymes needed for cell growth. It is not yet known whether lower-dose or standard dose regorafenib is more effective in treating patients with colorectal cancer. Clobetasol propionate is a steroid cream that is commonly used to treat a variety of skin conditions and may help prevent hand-foot skin reactions in patients receiving regorafenib.
Read the detailed description
PRIMARY OBJECTIVES:
- Evaluate the proportion of patients who complete 2 cycles of protocol treatment and initiate cycle 3 in arm A (pooled arm A1 and A2) and arm B (pooled arm B1 and B2).
SECONDARY OBJECTIVES:
- Evaluate outcome measures for efficacy in each arm including progression-free survival (PFS), time to progression (TTP), and overall survival (OS).
II. Compare between arms the cumulative dose and dose intensity received within the first two cycles.
III. Evaluate the proportion of patients in each arm that exhibit grade 3 palmar-plantar erythrodysesthesia syndrome (PPES) and/or fatigue, and make comparisons between regorafenib dosing strategies and pre-emptive versus (vs.) reactive strategies to address PPES.
IV. Compare quality of life (QOL) between treatment arms (regorafenib dosing strategies and preemptive vs. reactive PPES strategies) as measured by the Hand and Foot Syndrome (HFS)14, Brief Fatigue Inventory (BFI), and Linear Analogue Self-Assessment (LASA) questionnaires.
TERTIARY OBJECTIVES:
- Evaluate and compare trough minimum concentration (Cmin) pharmacokinetics (PK) during the first 2 treatment cycles for regorafenib and active metabolites M2, M5 between the low dose (dose escalation) and the standard dose cohorts, and correlate with toxicity profile.
II. Evaluate the correlation between PK parameters and tumor response/stable disease after the first two cycles.
III. Evaluate the correlation between PK parameters and PFS and OS. IV. Evaluate if trough (Cmin) concentrations are associated with patient-specific factors (such as ? but not limited to ? age and concomitant medications).
OUTLINE: Patients are randomized to 1 of 4 treatment arms.
ARM A1: Patients receive lower-dose regorafenib PO once daily (QD) on days 1-21 and pre-emptive clobetasol propionate given topically twice daily (BID) for 12 weeks, beginning on day 1 of regorafenib.
ARM A2: Patients receive lower-dose regorafenib PO as in Arm A1 and reactive clobetasol propionate given topically BID beginning on day 1 per physician discretion upon occurrence of PPES grade >= 1.
ARM B1: Patients receive standard dose regorafenib PO QD on days 1-21 and pre-emptive clobetasol propionate as in Arm A1.
ARM B2: Patients receive standard dose regorafenib PO as in Arm B1 and reactive clobetasol propionate as in Arm A2.
In all arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 2-6 months.
- Conditions
- Colon Adenocarcinoma, Rectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7
- Being tested
- Clobetasol Propionate, Pharmacological Study, Quality-of-Life Assessment, Regorafenib
- Medical subject headings
- Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Clobetasol PropionateDrug
Also called Olux-E
Given topically
Correlative studies
Quality-of-Life AssessmentOther
Also called Quality of Life Assessment
Ancillary studies
RegorafenibDrug
Also called BAY 73-4506, Stivarga
Given PO
| Study group | Role | What they receive |
|---|---|---|
| Arm A1 (lower-dose regorafenib, pre-emptive clobetasol) | Experimental | Patients receive lower-dose regorafenib PO QD on days 1-21 and pre-emptive clobetasol propionate given topically BID for 12 weeks, beginning on day 1 of regorafenib. Receives: Drug: Clobetasol Propionate; Other: Pharmacological Study; Other: Quality-of-Life Assessment; Drug: Regorafenib |
| Arm A2 (lower-dose regorafenib, reactive clobetasol) | Experimental | Patients receive lower-dose regorafenib PO as in Arm A1 and reactive clobetasol propionate given topically BID beginning on day 1 per physician discretion upon occurrence of PPES grade >= 1. Receives: Drug: Clobetasol Propionate; Other: Pharmacological Study; Other: Quality-of-Life Assessment; Drug: Regorafenib |
| Arm B1 (standard dose regorafenib, pre-emptive clobetasol) | Experimental | Patients receive standard dose regorafenib PO QD on days 1-21 and pre-emptive clobetasol propionate as in Arm A1. Receives: Drug: Clobetasol Propionate; Other: Pharmacological Study; Other: Quality-of-Life Assessment; Drug: Regorafenib |
| Arm B2 (standard dose regorafenib, reactive clobetasol) | Experimental | Patients receive standard dose regorafenib PO as in Arm B1 and reactive clobetasol propionate as in Arm A2. Receives: Drug: Clobetasol Propionate; Other: Pharmacological Study; Other: Quality-of-Life Assessment; Drug: Regorafenib |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of Patients in Each Arm Who Complete 2 Cycles of Protocol Treatment and Initiate Cycle 3
Fisher exact test will be used to detect a difference course 3 between arms (starting low dose [pooled arm A1 and A2] versus [vs.] standard dose [pooled arm B1 and B2]). The proportion of patients who complete 2 courses of protocol treatment and initiate course 3 will be computed by arm with its 95% confidence interval using exact method.
Measured: At 8 weeks
Secondary outcomes (8)
Overall Survival (OS)
OS is defined as the time from randomization to death due to any cause and will be estimated with Kaplan-Meier survival curves and differences between regorafenib arms (A vs. B) tested using log-rank tests, though these analyses are not powered for formal non-inferiority assessments.
Measured: Time from randomization to death due to any cause, assessed up to 2 years
Progression Free Survival (PFS)
PFS is defined as the time from randomization to the earlier of disease progression or death due to any cause, where progressed disease (PD) is defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and will be estimated with Kaplan-Meier survival curves and differences between regorafenib arms (A vs. B) tested using log-rank tests, though these analyses are not powered for formal non-inferiority assessments.
Measured: Time from randomization to the earlier of disease progression or death due to any cause, where progressed disease (PD) is defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, assessed up to 2 years
Time to Progression (TTP)
TTP is defined as the time from randomization to disease progression, where PD is defined by RECIST 1.1 and will be estimated with Kaplan-Meier survival curves and differences between regorafenib arms (A vs. B) tested using log-rank tests, though these analyses are not powered for formal non-inferiority assessments.
Measured: Time from randomization to disease progression, where PD is defined by RECIST 1.1, assessed up to 2 years
Cumulative (Total) Dose of Regorafenib Received by Patients in the First Two Cycles
Will be summarized with descriptive statistics and compared between regorafenib arms (A vs. B).
Measured: Up to 8 weeks
Dose Intensity of Regorafenib Received by Patients in the First Two Cycles as Measured by the Percentage of Planned Dose Received
Dose intensity of regorafenib received by patients in the first two cycles as measured by the percentage (%) of planned dose received
Measured: Up to 8 weeks
Proportion of Patients Overall and Within Each Arm Experiencing Grade 3 or 4 Hand and Foot Syndrome (HFS)
Will be computed with 95% confidence intervals.
Measured: 2 years
Quality of Life (QOL) (According to the HFS14 Total Score)
Patients will be descriptively compared between treatment arms and between HFS treatment strategies (pre-emptive vs. reactive) according to self-reported outcomes given on the HFS14 questionnaire. Results from the course 1 and 2 HSF14 questionnaires will also be summarized descriptively as they relate to the pre-emptive versus reactive palmar-plantar erythrodysesthesia syndrome (PPES) strategies. Total HFS-14 score was calculated by summing the scores of all items and adjusting to 100 by applying a rule of three. Total scores have a range of 2-100, with the higher the score, the greater the QoL impairment.
Measured: 8 weeks
Changes in QOL (According to the Linear Analogue Self-Assessment [LASA] Questionnaire)
Changes in QOL (according to the LASA questionnaire as measured by the overall QOL question) from baseline will be compared between the treatment arms using the Kruskal-Wallis test.
Measured: Baseline to 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Feb 2015 (estimated)
- Study start27 Mar 2015
- Primary completion1 Sep 2017
- Study completion2 Mar 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Colon AdenocarcinomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 123 participants (actual)
Sponsor and investigators
- Lead sponsor
- Academic and Community Cancer Research United
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Tanios Bekaii-Saab, Principal investigator, Academic and Community Cancer Research United
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02368886
- Sponsor's protocol ID
- RU021407I
- Other IDs
- NCI-2015-00011, RU021407I, P30CA015083
- Status last verified
- Jun 2025
- First submitted
- 16 Feb 2015
- Last updated
- 18 Jun 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Publications
Bekaii-Saab TS, Ou FS, Ahn DH, Boland PM, Ciombor KK, Heying EN, Dockter TJ, Jacobs NL, Pasche BC, Cleary JM, Meyers JP, Desnoyers RJ, McCune JS, Pedersen K, Barzi A, Chiorean EG, Sloan J, Lacouture ME, Lenz HJ, Grothey A. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol. 2019 Aug;20(8):1070-1082. doi: 10.1016/S1470-2045(19)30272-4. Epub 2019 Jun 28.
PubMed 31262657Weinberg BA, Hartley ML, Salem ME. Precision Medicine in Metastatic Colorectal Cancer: Relevant Carcinogenic Pathways and Targets-PART 2: Approaches Beyond First-Line Therapy, and Novel Biologic Agents Under Investigation. Oncology (Williston Park). 2017 Jul 15;31(7):573-80.
PubMed 28712102